Switch theme
Sign up to access all valuation multiples
PharmaSGP Holding SE is a pharmaceutical company. The company develops chemical-free, over-the-counter (OTC) drugs and healthcare products. The product portfolio includes RUBAXX for rheumatic pain Restaxil for nerve pain, and Deseo for sexual dysfunction. It has established various consumer brands in important indication areas, such as rheumatic and neuralgic pain or sexual weakness Also, the company offers products for skin aging and vertigo.
96
LTM Revenue $126M
LTM EBITDA $40.0M
$269M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PharmaSGP has a last 12-month revenue of $126M and a last 12-month EBITDA of $40.0M.
In the most recent fiscal year, PharmaSGP achieved revenue of $109M and an EBITDA of $38.3M.
PharmaSGP expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PharmaSGP valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $109M | $124M | XXX | XXX | XXX |
| Gross Profit | $63.2M | $82.5M | XXX | XXX | XXX |
| Gross Margin | 58% | 67% | XXX | XXX | XXX |
| EBITDA | $38.3M | $39.2M | XXX | XXX | XXX |
| EBITDA Margin | 35% | 32% | XXX | XXX | XXX |
| Net Profit | $11.5M | $12.8M | XXX | XXX | XXX |
| Net Margin | 11% | 10% | XXX | XXX | XXX |
| Net Debt | $68.9M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, PharmaSGP's stock price is EUR 24 (or $26).
PharmaSGP has current market cap of EUR 288M (or $309M), and EV of EUR 251M (or $269M).
See PharmaSGP trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $269M | $309M | XXX | XXX | XXX | XXX | $1.83 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, PharmaSGP has market cap of $309M and EV of $269M.
PharmaSGP's trades at 2.1x LTM EV/Revenue multiple, and 6.7x LTM EBITDA.
Analysts estimate PharmaSGP's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for PharmaSGP and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $269M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 6.9x | XXX | XXX | XXX |
| P/E | 14.7x | XXX | XXX | XXX |
| P/E/Growth | 1.0x | XXX | XXX | XXX |
| EV/FCF | 10.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPharmaSGP's NTM/LTM revenue growth is 7%
PharmaSGP's revenue per employee for the last fiscal year averaged $1.1M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, PharmaSGP's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate PharmaSGP's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for PharmaSGP and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 39% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 43% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 66% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PharmaSGP acquired XXX companies to date.
Last acquisition by PharmaSGP was XXXXXXXX, XXXXX XXXXX XXXXXX . PharmaSGP acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| Where is PharmaSGP headquartered? | PharmaSGP is headquartered in Germany. |
| How many employees does PharmaSGP have? | As of today, PharmaSGP has 96 employees. |
| Who is the CEO of PharmaSGP? | PharmaSGP's CEO is Ms. Natalie Weigand. |
| Is PharmaSGP publicy listed? | Yes, PharmaSGP is a public company listed on BER. |
| What is the stock symbol of PharmaSGP? | PharmaSGP trades under PSG ticker. |
| When did PharmaSGP go public? | PharmaSGP went public in 2020. |
| Who are competitors of PharmaSGP? | Similar companies to PharmaSGP include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of PharmaSGP? | PharmaSGP's current market cap is $309M |
| What is the current revenue of PharmaSGP? | PharmaSGP's last 12-month revenue is $126M. |
| What is the current EBITDA of PharmaSGP? | PharmaSGP's last 12-month EBITDA is $40.0M. |
| What is the current EV/Revenue multiple of PharmaSGP? | Current revenue multiple of PharmaSGP is 2.1x. |
| What is the current EV/EBITDA multiple of PharmaSGP? | Current EBITDA multiple of PharmaSGP is 6.7x. |
| What is the current revenue growth of PharmaSGP? | PharmaSGP revenue growth between 2023 and 2024 was 14%. |
| Is PharmaSGP profitable? | Yes, PharmaSGP is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
